Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Inks Deal with MultiPlan to Include MaterniT21 Plus Test

NEW YORK (GenomeWeb News) – Sequenom today announced an expanded agreement with healthcare cost management firm MultiPlan to include the MaterniT21 Plus LDT test for fetal aneuploidies.

As a result of the deal, MultiPlan's network of 900,000 providers will have access to Sequenom's test for trisomy 21, 18, and 13. The test was launched in October.

One of Sequenom's goals for 2012 is to sign two major national insurers as well as smaller payors in order to drive up adoption of the test. Earlier this week, the company increased its estimates for the number of billed MaterniT21 tests to 40,000 in 2012, up from a previous forecast of 25,000.